No Data
No Data
Jiangsu Kindk Biosciences Co., Ltd.'s 2024 interim report in full.
Jiangsu Kindstar Biotech Co., Ltd. Summary of 2024 Half-Yearly Report
Jindike (688670.SH): incurred a net loss of 40.8671 million yuan in the first half of the year.
On August 20th, Gelunhui reported that in the first half of 2024, Jindike (688670.SH) achieved revenue of 3.2882 million yuan, a decrease of 97.41% year-on-year; the net income attributable to shareholders of the listed company was -40.8671 million yuan.
Jindike (688670.SH): The controlling shareholder and joint actual controller renewed the joint control and concerted action agreement.
On July 25th, Gelunhui announced that on July 25th, 2024, the company received a notification from the company's controlling shareholder and co-controlling shareholder, Mr. Yu Jun and Mr. Zhang Liangbin, regarding the renewal of the "Joint Control and Consistent Action Agreement for Jiangsu Jindike Biotechnology Co., Ltd." (hereinafter referred to as the "Consistent Action Agreement"). The "Joint Control and Consistent Action Agreement" and the "Supplementary Agreement to the Joint Control and Consistent Action Agreement" signed by both parties before the company's initial public offering of stocks will expire on August 1st, 2024, for the development needs of the company's future.
Jindike (688670.SH): 79.0644 million restricted shares will be released on August 2.
On July 25th, Gelunhui reported that the total number of stocks listed for Jindike (688670.SH) was 79.0644 million. The date of the stock listing is August 2, 2024.
Jindike (688670.SH): Starting from June 12th, the prices of the quadrivalent influenza vaccine products will be adjusted.
On June 12th, Gelunhui announced that, based on the current market situation and the overall competitive landscape of the industry, and after careful consideration, the company has decided to adjust the price of its quadrivalent influenza vaccine products starting from June 12, 2024: the quadrivalent influenza split virus vaccine (adult formulation, pre-filled 0.5ml/syringe) will be adjusted to 88 yuan/syringe; the quadrivalent influenza split virus vaccine (adult formulation, vial 0.5ml/bottle) will be adjusted to 85 yuan/bottle. The above product prices do not include storage and transportation fees. If vaccine storage and transportation fees are charged in some areas, the quoted price will be adjusted accordingly.
No Data